ABSI vs RXRX
ABSI and RXRX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | ABSIABSCI CORP | RXRXRECURSION PHARMACEUTICALS, INC. |
|---|---|---|
| Market cap | $1.29B | — |
| P/S | 461.6x | — |
| Revenue growth (YoY) | -38.2% | 26.9% |
| Earnings growth (YoY) | -11.7% | -39.1% |
| EBIT margin | -4297.0% | -867.9% |
| ROE | -67.0% | -62.9% |
| ROIC | -71.9% | -174.7% |
| 1y total return | +187.3% | -46.7% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: ABSI vs RXRX
| 지표 | ABSI | RXRX |
|---|---|---|
| 최종 가치 | $3.8K | $818 |
| 총수익률 | -61.6% | -91.8% |
| CAGR | -17.5% | -39.5% |
| 변동성 | 98.4% | 93.4% |
| 샤프 | 0.25 | -0.14 |
| 소르티노 | 0.38 | -0.22 |
| 최대 낙폭 | -96.2% | -92.1% |
공통 거래일 1252일 기준, 2021-07-22 → 2026-07-17 · 무위험수익률 3.85% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)